European Journal of Cancer
Volume 41, Issue 13 , Pages 1980-1989 , September 2005

SERMs in chemoprevention of breast cancer

  • Milena Gasco

      Affiliations

    • Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, 16128 Genoa, Italy
    • ,
  • Alessandra Argusti

      Affiliations

    • Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, 16128 Genoa, Italy
    • ,
  • Bernardo Bonanni

      Affiliations

    • Division of Chemoprevention, European Institute of Oncology, 20141 Milan, Italy
    • ,
  • Andrea Decensi

      Affiliations

    • Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, 16128 Genoa, Italy
    • Division of Chemoprevention, European Institute of Oncology, 20141 Milan, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 010 563 4501; fax: +39 010 5748 1090.

Received 22 April 2005 ,Accepted 22 April 2005.

References 

  1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–1388
  2. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993–2000
  3. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–1467
  4. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: progress and promise. J Natl Cancer Inst. 1998;90:1514–1528
  5. O’Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res. 2002;8:314–346
  6. Kelloff GJ, Boone CW, Crowell JA, et al. Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem. 1996;25(Suppl.):1–28
  7. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351:1393–1396
  8. Yu H, Jin F, Shu XO, et al. Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev. 2002;11:705–712
  9. Toniolo P, Bruning PF, Akhmedkhanov A, et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer. 2000;88:828–832
  10. Li BD, Khosravi MJ, Berkel HJ, et al. Free insulin-like growth factor-I and breast cancer risk. Int J Cancer. 2001;91:736–739
  11. Del Giudice ME, Fantus IJ, Ezzat S, et al. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat. 1998;47:111–120
  12. Krajcik RA, Borofsky ND, Massardo S, et al. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:1566–1573
  13. Johansson H, Baglietto L, Guerrieri-Gonzaga A, et al. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer. Breast Cancer Res Treat. 2004;88:63–73
  14. Shi R, Yu H, McLarty J, et al. IGF-I and breast cancer: a meta-analysis. Int J Cancer. 2004;111:418–423
  15. Ren Z, Cai Q, Shu X, et al. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev. 2004;13:1290–1295
  16. Wedrén S, Lovmar L, Humphreys K, et al. Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res. 2004;6:R437–R449
  17. Arun B. Ductal lavage and risk assessment of breast cancer. Oncologist. 2004;9:599–605
  18. Herman JG. Circulating methylated DNA. Ann NY Acad Sci. 2004;1022:33–39
  19. Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst. 2000;92:1805–1811
  20. Jeronimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology. 2002;60:1131–1135
  21. Rykova EY, Laktionov PP, Skvortsova TE, et al. Extracellular DNA in breast cancer: cell surface-bound, tumour-derived extracellular DNA in blood of patients with breast cancer and non-malignant tumours. Ann NY Acad Sci. 2004;1022:217–220
  22. Ferguson AT, Evron E, Umbricht CB, et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA. 2000;97:6049–6054
  23. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. N Engl J Med. 2000;342:564–571
  24. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352:98–101
  25. Powles TJ, Eeles R, Salmon A, et al. Update of the Royal Marsden Hospital tamoxifen breast cancer chemoprevention trial. Proc Am Soc Clin Oncol. 2003;22:94;[Abstract 375]
  26. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomised trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst. 2003;95:160–165
  27. Decensi A, Maisonneuve P, Rotmensz N, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation. 2005;111:650–656
  28. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817–824
  29. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296–300
  30. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomised trial – Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189–2197
  31. Johnston CCJ, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomised, placebo-controlled trials. Arch Intern Med. 2000;160:3444–3450
  32. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat. 2001;65:125–134
  33. Martino S, Cauley JA, Barrett-Connor E, et al. Incidence of invasive breast cancer following 8 years of raloxifene therapy in postmenopausal women with osteoporosis: results from the Continuing Outcomes Relevant to Evista (CORE) Trial. Proc Am Soc Clin Oncol. 2004;23:97;[Abstract 1000]
  34. Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst. 1998;90:1461–1467
  35. Johnston SR, Haynes BP, Sacks NP, et al. Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer. Breast Cancer Res Treat. 1993;28:241–250
  36. Guerrieri-Gonzaga A, Baglietto L, Johansson H, et al. Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. Cancer Epidemiol Biomarkers Prev. 2001;10:967–970
  37. Breuer B, Wallenstein S, Anderson R. Effect of tamoxifen on bone fractures in older nursing home residents. J Am Geriatr Soc. 1998;46:968–972
  38. Decensi A, Robertson C, Viale G, et al. A randomised trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst. 2003;95:779–790
  39. Khan SA, Rogers MA, Khurana KK, et al. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst. 1998;90:37–42
  40. Guerrieri-Gonzaga A, Galli A, Rotmensz N, et al. The Italian breast cancer prevention trial with tamoxifen: findings and new perspectives. Ann NY Acad Sci. 2001;949:113–122
  41. Bonanni B, Serrano D, Cazzaniga M, et al. A biomarker trial of low-dose tamoxifen in HRT users. Proc Frontiers in Cancer Prev Res. 2004;69;[Abstract A2]
  42. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131–2139
  43. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  44. Coombes RC, Hall E, Gibson LJ, et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New Engl J Med. 2004;350:1081–1092
  45. Goss PE, Ingle JN, Martino S, et al. A randomised trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New Engl J Med. 2003;349:1793–1802
  46. Goss PE, Ingle JN, Martino S, et al. Updated analysis of the NCIC CTG MA 17 randomised placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proc Am Soc Clin Oncol. 2004;23:87;[Abstract 84]
  47. The Big 1-98 Collaborative Group. Letrozole versus Tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: a prospective randomized double blind phase III study. In: Primary therapy of early breast cancer conference, St. Gallen, Switzerland; 2005 [Abstract S4].
  48. Guerrieri-Gonzaga A, Decensi A, Serrano D, et al. Anastrozole and low dose tamoxifen in patients with breast carcinoma in situ: a pharmacokinetics and biomarker study. Proc Frontiers in Cancer Prev Res. 2004;69–70[Abstract A4]
  49. Costa A, Formelli F, Chiesa F, et al. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res. 1994;54:2032s–2037s
  50. Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene. 2003;22:7305–7315
  51. Maurer BJ, Metelitsa LS, Seeger RC, et al. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines. J Natl Cancer Inst. 1999;91:1138–1146
  52. Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett. 2004;206:169–180
  53. Lovat PE, Di Sano F, Corazzari M, et al. Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. J Natl Cancer Inst. 2004;96:1288–1299
  54. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science. 1998;279:563–566
  55. Ma J, Pollack MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3. J Natl Cancer Inst. 1999;91:620–625
  56. Hankinson SE, Willet WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet. 1998;351:1393–1396
  57. Giovannucci E, Pollack MN, Platz EA, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev. 2000;9:345–349
  58. Decensi A, Veronesi U, Miceli R, et al. Relationships between plasma insulin-like growth factor-1 and insulin-like growth factor binding prote-3 and second breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res. 2003;9:4722–4729
  59. Lotan R. Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J Natl Cancer Inst. 1995;87:1655–1657
  60. Mehta RG, Moon RC, Hawthorne M, et al. Distribution of fenretinide in the mammary gland of breast cancer patients. Eur J Cancer. 1991;27:138–141
  61. Veronesi U, De Palo G, Marubini E, et al. Randomised trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 1999;91:1847–1856
  62. Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al. A randomised 2×2 biomarker trial of low-dose tamoxifen and fenretinide in premenopausal women at high-risk for breast cancer. Proc Am Soc Clin Oncol. 2004;23:97;[Abstract 1001]
  63. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71
  64. Wooster R, Stratton MR. Breast cancer susceptibility: a complex disease unravels. Trends Genet. 1995;11:3–5
  65. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers – Breast Cancer Linkage Consortium. Lancet. 1994;343:692–695
  66. Easton DF, Steele L, Fields P, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet. 1997;61:120–128
  67. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91:1475–1479
  68. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998;351:316–321
  69. Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer. 1997;33:362–371
  70. Karp SE, Tonin PN, Begin LR, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer. 1997;80:435–441
  71. Loman N, Johannsson O, Bendahl PO, et al. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer. 1998;83:310–319
  72. Phillips KA, Andrulis IL, Goodwin PJ. Breast carcinomas arising in carriers of mutations in BRCA1 of BRCA2: are they prognostically different?. J Clin Oncol. 1999;17:3653–3663
  73. Wagner TM, Moslinger RA, Muhr D, et al. BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specificBRCA1 mutations and pathological characteristics. Int J Cancer. 1998;77:354–360
  74. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000;356:1876–1881
  75. Foulkes WD, Goffin J, Brunet JS, et al. Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of estrogen receptor status. J Natl Cancer Inst. 2002;94:1504–1506
  76. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286:2251–2256
  77. Fan S, Ma YX, Wang C, et al. P300 modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res. 2002;62:141–151
  78. Ferlini C, Scambia G, Marone M, et al. Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer. 1999;79:257–263
  79. Chan KC, Knox WF, Gee JM, et al. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res. 2002;62:122–128
  80. Davies G, Martin LA, Sacks N, et al. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol. 2002;13:669–678

PII: S0959-8049(05)00340-0

doi: 10.1016/j.ejca.2005.04.017

European Journal of Cancer
Volume 41, Issue 13 , Pages 1980-1989 , September 2005

Article Tools

* Image Usage & Resolution